Publication:
Relationships of Gut Microbiota Composition, Short-Chain Fatty Acids and Polyamines with the Pathological Response to Neoadjuvant Radiochemotherapy in Colorectal Cancer Patients.

Loading...
Thumbnail Image

Date

2021-09-02

Authors

Sánchez-Alcoholado, Lidia
Laborda-Illanes, Aurora
Otero, Ana
Ordóñez, Rafael
González-González, Alicia
Plaza-Andrades, Isaac
Ramos-Molina, Bruno
Gómez-Millán, Jaime
Queipo-Ortuño, María Isabel

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Emerging evidence has suggested that dysbiosis of the gut microbiota may influence the drug efficacy of colorectal cancer (CRC) patients during cancer treatment by modulating drug metabolism and the host immune response. Moreover, gut microbiota can produce metabolites that may influence tumor proliferation and therapy responsiveness. In this study we have investigated the potential contribution of the gut microbiota and microbial-derived metabolites such as short chain fatty acids and polyamines to neoadjuvant radiochemotherapy (RCT) outcome in CRC patients. First, we established a profile for healthy gut microbiota by comparing the microbial diversity and composition between CRC patients and healthy controls. Second, our metagenomic analysis revealed that the gut microbiota composition of CRC patients was relatively stable over treatment time with neoadjuvant RCT. Nevertheless, treated patients who achieved clinical benefits from RTC (responders, R) had significantly higher microbial diversity and richness compared to non-responder patients (NR). Importantly, the fecal microbiota of the R was enriched in butyrate-producing bacteria and had significantly higher levels of acetic, butyric, isobutyric, and hexanoic acids than NR. In addition, NR patients exhibited higher serum levels of spermine and acetyl polyamines (oncometabolites related to CRC) as well as zonulin (gut permeability marker), and their gut microbiota was abundant in pro-inflammatory species. Finally, we identified a baseline consortium of five bacterial species that could potentially predict CRC treatment outcome. Overall, our results suggest that the gut microbiota may have an important role in the response to cancer therapies in CRC patients.

Description

MeSH Terms

Aged
Case-Control Studies
Colorectal Neoplasms
Fatty Acids, Volatile
Feces
Female
Gastrointestinal Microbiome
Humans
Intestinal Mucosa
Male
Middle Aged
Neoadjuvant Therapy
Permeability
Polyamines
Treatment Outcome

DeCS Terms

CIE Terms

Keywords

SCFAs, colorectal cancer, gut microbiota, gut permeability, radiochemotherapy, treatment outcome

Citation